Zhuoran Qiao

This paper introduces a computational antibody design platform that generates drug-like antibodies with high developability and atomic accuracy, demonstrating its utility for challenging therapeutic targets.

This paper introduces Chai-2, a model that designs antibodies with a 16% hit rate, achieving success in 50% of targets without prior binders, and enables rapid validation in under two weeks.